Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Unknown 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 412Carcinoma, Non-Small-Cell Lung 285Prostatic Neoplasms 208Neoplasms 202Neoplasm Metastasis 179Melanoma 164Multiple Myeloma 158Colorectal Neoplasms 157Leukemia, Myeloid, Acute 143Lung Neoplasms 132Leukemia 126Lymphoma 118Pancreatic Neoplasms 117Recurrence 111Ovarian Neoplasms 111Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Non-Hodgkin 104Carcinoma, Renal Cell 104Brain Neoplasms 89Myelodysplastic Syndromes 88Precursor Cell Lymphoblastic Leukemia-Lymphoma 86Glioblastoma 84Lymphoma, Large B-Cell, Diffuse 80Lymphoma, Follicular 79Carcinoma, Hepatocellular 79Head and Neck Neoplasms 77Squamous Cell Carcinoma of Head and Neck 76Urinary Bladder Neoplasms 66Stomach Neoplasms 61Hodgkin Disease 59

Interventions

TroVax 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Terminated × Prostatic Hyperplasia × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡